Controlled infection immunization using delayed death drug treatment elicits protective immune responses to blood-stage malaria parasites.

Naturally acquired immunity to malaria is robust and protective against all strains of the same species of Plasmodium. This develops as a result of repeated natural infection, taking several years to develop. Evidence suggests that apoptosis of immune lymphocytes due to uncontrolled parasite growth contributes to the slow acquisition of immunity. To hasten and augment the development of natural immunity, we studied controlled infection immunization (CII) using low dose exposure to different parasite species ( P. chabaudi, P. yoelii or P. falciparum ) in two rodent systems (BALB/c and C57BL/6) and in human volunteers, with drug therapy commencing at the time of initiation of infection. CIIs with infected erythrocytes and in conjunction with doxycycline or azithromycin, which are 'delayed death' drugs targeting the parasite's apicoplast, allow extended exposure to parasites at low levels. In turn, this induces strong protection in all immunized mice against homologous challenge. We show that P. chabaudi/P. yoelii infection initiated at the commencement of doxycycline therapy leads to cellular or antibody-mediated protective immune responses in mice, with a broad Th1 cytokine response providing the best correlate of protection against homologous and heterologous species of Plasmodium P. falciparum CII with doxycycline was additionally tested in a pilot clinical study (n=4) and was found to be well tolerated and immunogenic, with immunological studies primarily detecting increased cellular-associated immune responses. Furthermore, we report that a single dose of the longer-acting drug, azithromycin, given to mice (n=5) as a single subcutaneous treatment at the initiation of infection controlled P. yoelii infection and protected all mice against subsequent challenge.